背景:溃疡性结肠炎(UC)是一种以非特异性炎症为特征的慢性炎症性肠病。由于UC的慢性性质和高复发率,管理UC面临重大挑战。天然靛蓝已成为临床UC治疗的潜在治疗剂,与其他治疗方法相比,在缓解难治性UC和维持缓解期方面具有优势。
目的:这篇综述旨在阐明靛蓝在UC治疗中潜在的治疗作用机制,评估其临床疗效,优势,和限制,并提供在UC管理中利用靛蓝的方法和策略的见解。
方法:从包括PubMed在内的知名在线数据库中收集了有关天然靛蓝的综合数据,GreenMedical,WebofScience,谷歌学者,中国国家知识基础设施数据库,和国家知识产权局。
结果:临床研究表明,靛蓝,单独或与其他药物联合使用,在UC治疗中产生有利的结果。其作用机制涉及AHR受体的调节,抗炎特性,调节肠道菌群,肠道屏障的恢复,和调节免疫力。尽管它在治疗难治性UC和延长缓解期方面有效,天然靛蓝治疗与不良反应有关,质量变化,药代动力学研究不足。
结论:靛蓝在UC治疗中的疗效与其调节AHR受体的能力密切相关,发挥抗炎作用,mcodulate肠道菌群,恢复肠道屏障,调节免疫力。针对目前的不足,包括不良反应,质量控制问题,药代动力学数据不足,对于优化靛蓝在UC管理中的临床应用至关重要。通过完善以患者为中心的治疗策略,天然靛蓝有望在UC治疗中得到更广泛的应用,从而减轻UC患者的痛苦。
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by non-specific inflammation. Managing UC presents significant challenges due to its chronic nature and high recurrence rates. Indigo naturalis has emerged as a potential therapeutic agent in clinical UC treatment, demonstrating advantages in alleviating refractory UC and maintaining remission periods compared to other therapeutic approaches.
OBJECTIVE: This review aims to elucidate the potential mechanisms underlying the therapeutic effects of indigo naturalis in UC treatment, assess its clinical efficacy, advantages, and limitations, and provide insights into methods and strategies for utilizing indigo naturalis in UC management.
METHODS: Comprehensive data on indigo naturalis were collected from reputable online databases including PubMed, GreenMedical, Web of Science, Google Scholar,
China National Knowledge Infrastructure Database, and National Intellectual Property Administration.
RESULTS: Clinical studies have demonstrated that indigo naturalis, either alone or in combination with other drugs, yields favorable outcomes in UC treatment. Its mechanisms of action involve modulation of the AHR receptor, anti-inflammatory properties, regulation of intestinal flora, restoration of the intestinal barrier, and modulation of immunity. Despite its efficacy in managing refractory UC and prolonging remission periods, indigo naturalis treatment is associated with adverse reactions, quality variations, and inadequate pharmacokinetic investigations.
CONCLUSIONS: The therapeutic effects of indigo naturalis in UC treatment are closely linked to its ability to regulate the AHR receptor, exert anti-inflammatory effects, mcodulate intestinal flora, restore the intestinal barrier, and regulate immunity. Addressing the current shortcomings, including adverse reactions, quality control issues, and insufficient pharmacokinetic data, is crucial for optimizing the clinical utility of indigo naturalis in UC management. By refining patient-centered treatment strategies, indigo naturalis holds promise for broader application in UC treatment, thereby alleviating the suffering of UC patients.